Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The *Streptococcus pneumoniae* polysaccharide refers to the capsular polysaccharides that form the outermost layer of the bacterium. This capsule is a polymeric, surface-exposed carbohydrate structure that encapsulates each bacterial cell. The capsule is the major virulence factor, protecting bacteria from host immune responses. There are 98 recognized capsular polysaccharide serotypes. These serotypes are targets for pneumococcal vaccines, including polysaccharide-only and conjugate vaccines. Protection conferred by these vaccines is serotype-specific. Widespread vaccine use has led to serotype replacement.
Vaccines stimulate the production of serotype-specific antibodies that promote opsonophagocytosis and complement-mediated killing of Streptococcus pneumoniae. Antibodies bind to the capsular polysaccharide, facilitating phagocytosis and destruction of the bacteria by immune cells.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Streptococcus pneumoniae Polysaccharide (Multiple Serotypes) (PnPs).